Announcements Trials

Conditions

Gastrointestinal 22Thoracic 17Other 16Genitourinary 14Gynecologic 13Dermatologic 12Head & Neck 7Breast 4Lymphoid 4CNS 2Endocrine 2Sarcoma 2

Drug Classes

Anti-CD19 CAR T-cell 14Anti-CD20 14BTK inhibitor 13Anti-CD20-CD3 bispecific 5Anti-CD30 ADC 5Immunomodulatory drugs (IMiDs) 5Anti-PD-1 4Bcl-2 inhibitor 4Nitrogen mustard 3PI3K delta inhibitor 3Anthracycline 2Anti-CD19 2Anti-CD19-CD3 bispecific 2Anti-CD22 ADC 2Anti-CD79B ADC 2Asparagine-specific enzyme 2ALK inhibitor 1Anti-CCR4 1Anti-CD19 ADC 1Anti-CD22 immunotoxin 1Bcr-Abl inhibitor 1EZH inhibitor 1FGFR inhibitor 1HDAC inhibitor 1KMT2A inhibitor 1Proteasome inhibitor 1XPO1 inhibitor 1
Anti-PD-1 × Lymphoid × Clear all

4 Announcements

2026-03-20

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

Drugs
Opdivo (nivolumab) · Anti-PD-1 antibody, doxorubicin · Anthracycline
Condition
Lymphoid
2020-10-14

FDA extends approval of pembrolizumab for classical Hodgkin lymphoma

Trial
MK-3475-204
Drug
KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition
Lymphoid
2018-06-13

FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL

Trial
MK-3475-170
Drug
Keytruda (pembrolizumab) · Anti-PD-1 antibody
Condition
Lymphoid
2016-05-17

Nivolumab (Opdivo) for Hodgkin Lymphoma

Drug
Opdivo (nivolumab) · Anti-PD-1 antibody
Condition
Lymphoid
Data powered by HemOnc (CC BY 4.0) Colophon ⚡